Get the Stockscreener App
18.07
1.18%
0.21
Rapport Therapeutics Inc stock is traded at $18.07, with a volume of 514.15K.
It is up +1.18% in the last 24 hours and down -18.57% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$17.86
Open:
$17.57
24h Volume:
514.15K
Relative Volume:
3.45
Market Cap:
$660.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.73%
1M Performance:
-18.57%
6M Performance:
-18.53%
1Y Performance:
+0.00%
1-Day Range:
$17.52
$19.09
1-Week Range:
$17.50
$20.25
52-Week Range:
$16.55
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
18.07 | 660.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
Charles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Charles Schwab Investment Management Inc. Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - The Manila Times
(RAPP) Proactive Strategies - Stock Traders Daily
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth - Simply Wall St
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn - Yahoo Finance
Rapport Therapeutics Presents Data Demonstrating Consistent - GlobeNewswire
Rapport Therapeutics Breakthrough: New Epilepsy Treatment Biomarker Shows Strong Clinical Seizure Correlation | RAPP Stock News - StockTitan
Maven Securities LTD Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Fmr LLC Raises Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics' Lock-Up Period To Expire on December 4th (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics’ Lock-Up Period Will Expire on December 4th (NASDAQ:RAPP) - Defense World
Two new option listings and one option delisting on November 21st - TipRanks
Rapport Therapeutics Reports Q3 Financials and Strategic Updates - MSN
LMR Partners LLP Sells 30,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
(RAPP) Investment Analysis and Advice - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.5% – Should You Sell? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5%Time to Sell? - MarketBeat
Cormorant Asset Management's Strategic Acquisition in Rapport Th - GuruFocus.com
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Phase 2a Epilepsy Drug Data at Major Conference | RAPP Stock News - StockTitan
FMR LLC's Strategic Acquisition in Rapport Therapeutics Inc - GuruFocus.com
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
(RAPP) Investment Report - Stock Traders Daily
Rapport Therapeutics Inc (RAPP) Quarterly 10-Q Report - Quartzy
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update - The Manila Times
Rapport (RAPP) Hit With FDA Hold Despite $320M Cash Position; Q3 Loss Widens | RAPP Stock News - StockTitan
Rapport Therapeutics to Present at Stifel Healthcare - GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November - StockTitan
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Still a Buy? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
SG Americas Securities LLC Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) Trading Report - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.2%Here's Why - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownShould You Sell? - MarketBeat
Jones Trading Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7%Time to Sell? - MarketBeat
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - MSN
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Millennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Up 32.4% in September - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3%What's Next? - MarketBeat
75,516 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by The Manufacturers Life Insurance Company - MarketBeat
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director |
Jun 10 '24 |
Buy |
17.00 |
558,824 |
9,500,008 |
1,863,327 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):